MedTrace Logo

Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy

NCT00767689 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-06-15

No results posted yet for this study

Summary

Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and feet, a condition called Hand and Foot syndrome. patients , starting capecitabine chemotherapy for their cancer, will participate in this study at John H. Stroger Jr. Hospital of Cook County. They will be randomized to receive either vitamin B6 or a placebo. investigators and patients will be blinded to the intervention.

Conditions

  • Hand and Foot Syndrome

Interventions

DRUG

Vitamin B 6

vitamin b6 100 mg po daily

DRUG

placebo

placebo is given in the placebo arm

Sponsors & Collaborators

  • Cook County Health

    lead OTHER_GOV

Principal Investigators

  • Thomas Lad, MD · Cook County Health Oncology NCORP

  • Susan McDunn, MD · Cook County Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-21
Primary Completion
2009-03-18
Completion
2010-03-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00767689 on ClinicalTrials.gov